AN2 Therapeutics begins first-in-human trial of oral AN2-502998 for chagas disease
Phase 1 dosing is expected to finish by the end of 2025
Phase 1 dosing is expected to finish by the end of 2025
Alkem’s domestic business grew 9.7 per cent versus the Indian pharmaceutical market growth of 8.5 per cent
During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site
The new facility will enhance AbbVie’s chemical synthesis capacity to support domestic production of current and next-generation neuroscience, immunology, and oncology medicines
The conference will explore the path to India’s first billion-dollar drug, evolution towards value-based healthcare, biotech breakthroughs, and the role of AI and LLMs in care delivery
Rivaroxaban is used to treat venous thromboembolism
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
Under an exclusive distribution agreement, Sartorius Stedim Biotech will offer Nanotein’s lead products globally
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Norepinephrine Bitartratein 5% Dextrose of Baxter Healthcare Corp
Subscribe To Our Newsletter & Stay Updated